Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech to Webcast Presentation From 2006 BIO CEO and Investor Conference
Feb 8, 2006
|
65.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's chief executive officer, will present at the 2006 BIO CEO and Investor Conference on February 15, 2006 at 11:00 a.m. EST in New York City. Mr. Mc...
|
|
|
Corgentech Reports Clinical Data From Phase 1/2 Trials of Avrina(TM), Drug Candidate for Eczema
Feb 7, 2006
|
72.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today reported clinical data from two Phase 1/2 clinical trials of Avrina, Corgentech's NF-kappaB Decoy drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema that affects about 52 m...
|
|
|
Corgentech Announces Management Promotions
Jan 19, 2006
|
70.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Jan 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today announced the election of four individuals to vice president-level positions. The appointments include the promotions of Rolf O. Ehrhardt, M.D., Ph.D. to vice president, preclinical development; Melissa Morandi to vice p...
|
|
|
Corgentech and AlgoRx Complete Merger Creating Late-Stage Company Addressing Pain Management and Inflammation
Dec 16, 2005
|
73.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif. and SECAUCUS, N.J., Dec 16, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) and AlgoRx Pharmaceuticals, Inc. announced today that following stockholder approval of the merger by the stockholders of both companies, the merger was completed on December 15, 2005. The merger creates a l...
|
|
|
Corgentech and AlgoRx Complete Enrollment for Phase 1/2 Trial of Avrina(TM), New Drug Candidate for Eczema
Dec 6, 2005
|
74.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif. and SECAUCUS, N.J., Dec 06, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) and AlgoRx Pharmaceuticals, Inc. today announced that enrollment has been completed for the second of two multi-center Phase 1/2 clinical trials of Avrina, Corgentech's NF-kappaB Decoy drug candidate for the...
|
|
|
Click here to download our most recent fact sheet.